Samuel D. Stanton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samuel D. Stanton has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Martin Watkins
Genentech
2 shared publications - Franziska Seeger
Genentech
2 shared publications Henri Dwyer
2 shared publications- Homa MohammadiPeyhani
Prescient Design, Genentech
2 shared publications - Jack Bevers
Antibody Engineering, Genentech, South San Francisco, USA
2 shared publications - Joseph Kleinhenz
Prescient Design, Genentech, South San Francisco, CA, USA
2 shared publications
Latest Publications
- Open Access
CDR Conformation Aware Antibody Sequence Design with ConformAb
Antibody lead optimization methods seek to enhance a lead candidate's therapeutic properties through targeted sequence mutation. However, the mutations introduced during this process can inadvertently induce structural changes that disrupt binding, particularly by altering CDR loop conformations which destabilize CDR-target binding interactions. To address this, we present ConformAb, a guided discrete diffusion model for designing antibody sequences that explicitly conform to the CDR canonical conformation of the lead. With seed sequences as the starting point, we show that our method is capable of generating 3-5× better binders that conform to the same CDR backbone structure in a one-shot design setup, and in some cases, binders with better affinity than seed repertoire picks without any target-specific data included in training. Across the targets tested, ConformAb demonstrated binding rates ranging from 15-60% in wet lab experiments, a result obtained using fewer than 100 designs for each target. ConformAb offers a unique one-shot approach for antibody lead optimization in data-scarce scenarios where experimental/repertoire data cannot be leveraged for model training.
Open AccessCDR Conformation Aware Antibody Sequence Design with ConformAb
Antibody lead optimization methods seek to enhance a lead candidate's therapeutic properties through targeted sequence mutation. However, the mutations introduced during this process can inadvertently induce structural changes that disrupt binding, particularly by altering CDR loop conformations which destabilize CDR-target binding interactions. To address this, we present ConformAb, a guided discrete diffusion model for designing antibody sequences that explicitly conform to the CDR canonical conformation of the lead. With seed sequences as the starting point, we show that our method is capable of generating 3-5× better binders that conform to the same CDR backbone structure in a one-shot design setup, and in some cases, binders with better affinity than seed repertoire picks without any target-specific data included in training. Across the targets tested, ConformAb demonstrated binding rates ranging from 15-60% in wet lab experiments, a result obtained using fewer than 100 designs for each target. ConformAb offers a unique one-shot approach for antibody lead optimization in data-scarce scenarios where experimental/repertoire data cannot be leveraged for model training.
- Open Access
Lab-in-the-loop therapeutic antibody design with deep learning
Therapeutic antibody design is a complex multi-property optimization problem with substantial promise for improvement with the application of machine-learning methods. Towards realizing that promise, we introduce “Lab-in-the-loop,” a new approach that orchestrates state-of-the-art repertoire mining methods, generative machine learning models, multi-task property predictors, active learning ranking and selection, and in vitro experimentation in a semi-autonomous, iterative optimization loop. By automating the design of antibody variants, property prediction, ranking and selection of designs to assay in the lab, and ingestion of in vitro data, we enable an end-to-end approach to developing computationally-informed therapeutic antibody design pipelines. We apply lab-in-the-loop to eleven seed antibodies obtained via animal immunization with four clinically relevant antigen targets: EGFR, IL-6, HER2, and OSM. Over 1,800 unique antibody variants are tested throughout four rounds of iterative optimization identifying 3–100× better binding variants for all targets and 10/11 seeds, with the best binders exceeding 100 pM affinity, demonstrating a process by which end-to-end machine learning can be developed for therapeutic antibody development.
Open AccessLab-in-the-loop therapeutic antibody design with deep learning
Therapeutic antibody design is a complex multi-property optimization problem with substantial promise for improvement with the application of machine-learning methods. Towards realizing that promise, we introduce “Lab-in-the-loop,” a new approach that orchestrates state-of-the-art repertoire mining methods, generative machine learning models, multi-task property predictors, active learning ranking and selection, and in vitro experimentation in a semi-autonomous, iterative optimization loop. By automating the design of antibody variants, property prediction, ranking and selection of designs to assay in the lab, and ingestion of in vitro data, we enable an end-to-end approach to developing computationally-informed therapeutic antibody design pipelines. We apply lab-in-the-loop to eleven seed antibodies obtained via animal immunization with four clinically relevant antigen targets: EGFR, IL-6, HER2, and OSM. Over 1,800 unique antibody variants are tested throughout four rounds of iterative optimization identifying 3–100× better binding variants for all targets and 10/11 seeds, with the best binders exceeding 100 pM affinity, demonstrating a process by which end-to-end machine learning can be developed for therapeutic antibody development.